<DOC>
	<DOCNO>NCT00241358</DOCNO>
	<brief_summary>The purpose study determine peripheral blood cell collect follow AMD3100 mobilization use safely hematopoietic cell transplantation HLA-matched recipient .</brief_summary>
	<brief_title>Study Evaluating AMD3100 Transplantation Sibling Donor Stem Cells Patients With Hematological Malignancies</brief_title>
	<detailed_description>This study determine peripheral blood cell collect follow AMD3100 mobilization use safely hematopoietic cell transplantation HLA-matched recipient .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>JM 3100</mesh_term>
	<criteria>Donor criterion : Donor 18 70 year age inclusive If female childbearing age , must : nonpregnant , breast feeding use adequate contraception Donor 6/6 HLAmatched sibling willing donate peripheral blood stem cell transplant Donor must willing provide write informed consent . Adequate cardiac function history congestive heart failure history atrial fibrillation ventricular tachyarrhythmia . Adequate renal function define serum creatinine clearance ≥75 % normal ( CockcroftGault equation ) Adequate hepatic function define total bilirubin &lt; 2x normal absence hepatic fibrosis/cirrhosis Adequate neurologic function define : No evidence severe central peripheral neurologic abnormality . No history cerebrovascular accident seizure disorder require anticonvulsant medication Must HIV1 &amp; 2 antibody , HIV1 antigen , HTLVI &amp; II antibody seronegative , FDA license test . Must ECOG performance status 0 1 Must demonstrate ability compliant study regimen . Must active infection time study entry Not active alcohol substance abuse within 6 month study entry Not currently enrol another investigational agent study Not medical condition , , opinion clinical investigator , would interfere his/her evaluation Recipient criterion : 18 65 year age inclusive Willing 6/6 HLAmatched sibling willing donate PBSC transplant Provide sign inform consent If female childbearing age , must : nonpregnant , breast feeding , use adequate contraception Patient must one follow diagnosis : AML 1st subsequent remission relapse ALL 1st subsequent remission relapse MDS intermediate 1 2 , high risk International Prognostic Scoring System CML accelerate second chronic phase NHL HD 2nd great complete remission , partial remission , refractory relapse CLL Rai Stage 24 , fail least 2 prior regimen MM Stage 23 Adequate cardiac function leave ventricular ejection fraction ≥ 40 % Adequate pulmonary function define : No severe symptomatic restrictive obstructive lung disease , formal pulmonary function test show forced expiratory volume 1 second ( FEV1 ) ≥50 % predicted diffusion capacity lung carbon monoxide ( DLCO ) ≥40 % predict , correct hemoglobin Adequate renal function define serum creatinine clearance ≥75 % normal ( CockcroftGault equation ) Adequate hepatic function define total bilirubin &lt; 2x normal absence hepatic fibrosis/cirrhosis Adequate neurologic function define evidence severe central peripheral neurologic abnormality . Patients history previous central nervous system tumor involvement eligible provide without symptom sign CNS free disease lumbar puncture CT scan brain No evidence active infection time transplant preparative regimen time transplantation Patient must HIV1 &amp; 2 antibody , HIV1 antigen , HTLVI &amp; II antibody seronegative , FDA license test ECOG performance status 0 1 Must demonstrate ability compliant medical regimen Not active alcohol substance abuse within 6 month study entry Not concurrently enrol another study involve investigational agent Not medical condition , , opinion clinical investigator , would interfere evaluation patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Plerixafor</keyword>
	<keyword>Stem cell transplantation</keyword>
	<keyword>Stem cell</keyword>
	<keyword>Mobilization</keyword>
</DOC>